TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 35324339
Drug: Tapering group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tapering group
Study: 33375899
Drug: Compassion-Focused Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compassion-Focused Therapy (CFT) - 8 sessions
Study: 33375899
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group - no therapy
Study: 33091587
Drug: Intervention group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention group receiving EHR-based best practice alert and psychiatrist review of prescriptions.
Study: 33149136
Drug: Antibiotic prophylaxis
Normalized name: STONE PROPHYLAXIS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic prophylaxis at the start of anti‐myeloma treatment
Study: 34529869
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy of transobturator tape sling (TOT) and low-dose Abobotulinumtoxin-A injection (300 U injected in 20–30 sites)
Study: 34529869
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (Part 2)
Study: 33632930
Drug: Doxorubicin at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxorubicin at 75 mg/m2 for eight cycles
Study: 33632930
Drug: Doxorubicin at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxorubicin at 75 mg/m2 for eight cycles with dexrazoxane coadministration
Study: 35882292
Drug: CBD supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: CBD supplement (Hemp Extract, 150 mg)
Study: 35882292
Drug: Control (supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (supplement pellets without CBD)
Study: 32664094
Drug: Intravenous phenylephrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous phenylephrine infusion (0.5 μg/kg/min) for 5 minutes before BCP
Study: 32664094
Drug: Intravenous phenylephrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous phenylephrine infusion (1.0 μg/kg/min) for 5 minutes before BCP
Study: 34261364
Drug: Methylnaltrexone (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylnaltrexone (0.3 mg/kg IV)
Study: 33350782
Drug: Pinaverium bromide
Normalized name: pinaverium bromide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pinaverium bromide tablets placebo
Study: 33350782
Drug: Pinaverium bromide
Normalized name: pinaverium bromide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pinaverium bromide tablets
Study: 36174595
Drug: Artemether-lumefantrine (3-day
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artemether-lumefantrine (3-day course of twice-daily dosing followed by weekly dosing for 4 weeks)
Study: 36174595
Drug: Multivitamin (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multivitamin (no antimalarial activity)
Study: 35509395
Drug: High-flow nasal
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-flow nasal oxygen (HFNO) at 40 L min−1
Study: 32838710
Drug: Capsinoids (CSN)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsinoids (CSN) 12 mg, single dosage
Study: 32838710
Drug: Placebo capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules with a high‐carbohydrate meal (2 g carb/kg bodyweight)
Study: 33256506
Drug: Breviscapine (BRE)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Breviscapine (BRE) 120 mg daily (40 mg, three times a day) for 14 days
Study: 33256506
Drug: MDR1 C3435T
Approvals — FDA: no, EMA: no, PMDA: no
Description: MDR1 C3435T gene polymorphisms (CC, CT, TT genotypes)
Study: 36319585
Drug: Olive leaf
Normalized name: OLIVE LEAF
DrugBank: Olea europaea leaf (DB14745)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olive leaf extract 250 mg every 12 hours for five days
Study: 36319585
Drug: Olive leaf
Normalized name: OLIVE LEAF
DrugBank: Olea europaea leaf (DB14745)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olive leaf extract 500 mg every 12 hours for five days
Study: 33888191
Drug: Moderate levels
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate levels of daily physical activity
Study: 33888191
Drug: High levels
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High levels of daily physical activity
Study: 34399702
Drug: Physiotherapist-led management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physiotherapist-led management (Personalised Hip Therapy - PHT)
Study: 32000729
Drug: Stepping Stones
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stepping Stones Triple P (SSTP) parenting therapy (nine weeks, six group sessions and three individualised sessions) in addition to Treatment as Usual
Study: 32000729
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as Usual only (other available services in each location)
Study: 35812678
Drug: Psychosocial intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Psychosocial intervention (administered in eight sessions biweekly over 4 weeks)
Study: 39707490
Drug: Patients receiving
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients receiving antibiotics
Study: 35738969
Drug: BCG intradermal
Normalized name: Tice BCG Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCG intradermal vaccine
Study: 33486385
Drug: Cognitive‐behavioral group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive‐behavioral group therapy (CBGT) and Mindfulness‐based stress reduction (MBSR)
Study: 32761337
Drug: Guilingji Capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guilingji Capsules (GLJC) 0.6 g once a day and 19.2 mg of Gingko biloba extract mimetic 3 times a day
Study: 32761337
Drug: Guilingji Capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guilingji Capsules (GLJC) mimetic 0.6 g once a day and 19.2 mg of Gingko biloba extract in tablet form 3 times a day
Study: 36161864
Drug: OMEGA group
Approvals — FDA: no, EMA: no, PMDA: no
Description: OMEGA group (n = 14; 2234 mg of EPA and 916 mg of DHA daily)
Study: 36161864
Drug: MCT group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: MCT group (n = 12; 4000 mg of MCT daily)
Study: 33368399
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of volume as predictor for smaller lesions and selected features for larger lesions
Study: 36206888
Drug: Imagery focussed
Normalized name: AVOBENZONE 0.2 g in 1 g / BUTYLENE GLYCOL 0.1 g in 1 g TOPICAL CREAM [Focused Corrective]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imagery focussed cognitive therapy (ImCT)
Study: 34961942
Drug: 0.8% HA
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.8% HA gel applied onto the collagen matrix three times per day for 7 days
Study: 34961942
Drug: No gel
DrugBank: Nitric Oxide (DB00435)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: No gel application
Study: 36396084
Drug: Photodynamic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photodynamic therapy (660nm, 400mW/cm2, 300 seconds, methylene blue 0.01%)
Study: 36396084
Drug: Mupirocin (twice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mupirocin (twice a day for 5 days)
Study: 33074590
Drug: linagliptin 5
Normalized name: linagliptin 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: linagliptin 5 mg/d
Study: 34542305
Drug: Fluticasone propionate/Salmeterol
Normalized name: fluticasone propionate/salmeterol 100/50 MCG/INHAL Dry Powder Inhaler, 14 Blisters
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluticasone propionate/Salmeterol (FP/Salm) with as-needed short acting beta-2 agonist (SABA)
Study: 34542305
Drug: Budesonide/Formoterol (BUD/Form)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide/Formoterol (BUD/Form) Maintenance And Reliever Therapy (MART)
Study: 36102582
Drug: Ultrasound-guided anterior
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound-guided anterior quadratus lumborum block (LAL-QLB) with intravenous analgesia
Study: 34049123
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of assertiveness training and SBAR technique
Study: 35197082
Drug: Allopurinol (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allopurinol (20 mg/kg, administered intravenously in 2 doses early postnatally and 3 doses perioperatively)
Study: 32029498
Drug: 1500 mg
Normalized name: inulin 1500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1500 mg TXA
Study: 36225762
Drug: Text4Hope intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Text4Hope intervention group (IG) receiving once-daily supportive text messages for 6 weeks
Study: 36199051
Drug: Biomechanical markers
Normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biomechanical markers (e.g., flexion during loading)
Study: 32207709
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment complex (STC) + 5% brine electrophoresis by sinusoidal modulated currents, sage and sea baths
Study: 32207709
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment complex (STC)
Study: 35849214
Drug: Fast infusion
Normalized name: Fast Freeze
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fast infusion of 20% albumin (3 mL/kg over 30 min)
Study: 35849214
Drug: Slow infusion
Normalized name: Slow Sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow infusion of 20% albumin (3 mL/kg over 120 min)
Study: 35849214
Drug: Fast infusion
Normalized name: Fast Freeze
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fast infusion of 20% albumin
Study: 35849214
Drug: Slow infusion
Normalized name: Slow Sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow infusion of 20% albumin
Study: 33537000
Drug: Clomiphene Citrate
Normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clomiphene Citrate (CC) 50mg/day
Study: 32103160
Drug: 30% oral
Normalized name: Lactobacillus Acidophilus/Lactobacillus Bifidus 70%-30% Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30% oral dextrose
Study: 32103160
Drug: 30% oral
Normalized name: Lactobacillus Acidophilus/Lactobacillus Bifidus 70%-30% Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30% oral dextrose and facilitated tucking
Study: 32062862
Drug: Exenatide extended
Normalized name: Exenatide
DrugBank: Exenatide (DB01276)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Exenatide extended release 2 mg
Study: 34571011
Drug: Wii Fit
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Wii Fit rehabilitation program (30 minutes) in addition to standard physical therapy program (SPTP) (60 minutes), 3 sessions a week for 12 weeks.
Study: 34571011
Drug: Standard physical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard physical therapy program (SPTP) only, 3 sessions a week for 12 weeks.
Study: 33429174
Drug: Mometasone furoate
Normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mometasone furoate nasal spray (2 puffs of 100 µg once daily in each nostril for 3 weeks) with olfactory training
Study: 33567890
Drug: Sumatriptan (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sumatriptan (4 mg intravenous infusion over 10 min)
Study: 33567890
Drug: Placebo (intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (intravenous infusion over 10 min)
Study: 33122353
Drug: Experimental agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental agents with single-agent activity classified as active
Study: 33122353
Drug: Inactive agents
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactive agents
Study: 33122353
Drug: Agents without
Normalized name: threonine
DrugBank: Threonine (DB00156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Agents without known single-agent activity (pooled inactive and indeterminate)
Study: 35637106
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg caffeine capsule
Study: 32078486
Drug: Dual antiplatelet
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual antiplatelet therapy (DAPT) with aspirin plus clopidogrel
Study: 32352505
Drug: Concomitant treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concomitant treatment with 4 cycles of nivolumab and doxorubicin, vinblastine, and dacarbazine (N-AVD)
Study: 32352505
Drug: Sequential treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential treatment with 4 doses of nivolumab, 2 cycles of N-AVD, and 2 cycles of AVD followed by 30-Gy involved-site radiotherapy
Study: 32352505
Drug: Nivolumab monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab monotherapy (4 doses)
Study: 35193902
Drug: SPEAKS intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SPEAKS intervention (weekly psychotherapy lasting nine to 12 months)
Study: 33570488
Drug: Dopamine agonists
Normalized name: Dopamine agonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dopamine agonists and clonazepam prescriptions
Study: 33570488
Drug: Cumulative prescription
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cumulative prescription dose of medication
Study: 34807760
Drug: PLG0206 (0.05,
Approvals — FDA: no, EMA: no, PMDA: no
Description: PLG0206 (0.05, 0.125, 0.25, 0.5, or 1 mg/kg)
Study: 34807760
Drug: PLG0206 (0.05
Approvals — FDA: no, EMA: no, PMDA: no
Description: PLG0206 (0.05 to 1.0 mg/kg)
Study: 33270835
Drug: Internal Hexagon
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internal Hexagon (IH) connection implants
Study: 33270835
Drug: Internal Conical
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internal Conical (IC) connection implants
Study: 35280228
Drug: Both doses
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both doses of vitamin D3 supplementation
Study: 35280228
Drug: Lower dose
Normalized name: flowers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower dose (5,000 IU)
Study: 35280228
Drug: Higher dose
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher dose (50,000 IU)
Study: 35770374
Drug: Oral cannabis
Normalized name: Medical Cannabis
DrugBank: Medical Cannabis (DB14009)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral cannabis (0, 10 and 25 mg ∆9-THC)
Study: 35770374
Drug: Vaporized cannabis
Normalized name: Medical Cannabis
DrugBank: Medical Cannabis (DB14009)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaporized cannabis (0, 5 and 20 mg ∆9-THC)
Study: 35770374
Drug: Vaporized cannabis
Normalized name: Medical Cannabis
DrugBank: Medical Cannabis (DB14009)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaporized cannabis administration
Study: 32443332
Drug: Acitretin Capsule
Normalized name: Acitretin Capsules
DrugBank: Acitretin (DB00459)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acitretin Capsule
Study: 35801865
Drug: Individually tailored
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individually tailored interventions (physical activity, cognitive behaviour therapy for insomnia, computerized memory training, cognitive behavioural therapy for self‐esteem)
Study: 32756479
Drug: Normal daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal daily habits (Control Group)
Study: 34585396
Drug: Ibudilast (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibudilast (50 mg, twice daily; n = 20)
Study: 34585396
Drug: Ibudilast (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibudilast (50 mg, twice daily)
Study: 36056577
Drug: PSA <3
Approvals — FDA: no, EMA: no, PMDA: no
Description: PSA <3 ng/mL
Study: 36056577
Drug: Baseline PSA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline PSA 0 to 0.99 ng/mL
Study: 36056577
Drug: Baseline PSA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline PSA 1.0 to 1.99 ng/mL
Study: 36056577
Drug: Baseline PSA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline PSA 2 to 2.99 ng/mL
Study: 36056577
Drug: PSA <1
Approvals — FDA: no, EMA: no, PMDA: no
Description: PSA <1 ng/mL
Study: 36056577
Drug: PSA 2
Normalized name: Prednisolone Sodium Phosphate
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PSA 2 to 2.99 ng/mL
Study: 37949617
Drug: TIL therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: TIL therapy
Study: 32896456
Drug: qHBsAg <8
Approvals — FDA: no, EMA: no, PMDA: no
Description: qHBsAg <8 IU/mL in training set
Study: 32896456
Drug: qHBsAg <8
Approvals — FDA: no, EMA: no, PMDA: no
Description: qHBsAg <8 IU/mL in validation set
Study: 32896456
Drug: qHBsAg cutoff
Normalized name: HBSAG
DrugBank: Hepatitis B Vaccine (Recombinant) (DB11627)
Approvals — FDA: no, EMA: no, PMDA: no
Description: qHBsAg cutoff of 8 IU/mL
Study: 32896456
Drug: qHBsAg cutoff
Normalized name: HBSAG
DrugBank: Hepatitis B Vaccine (Recombinant) (DB11627)
Approvals — FDA: no, EMA: no, PMDA: no
Description: qHBsAg cutoff of 200 IU/mL in training set
Study: 32721845
Drug: Magnesium sulphate
Normalized name: Magnesium sulphate
DrugBank: Magnesium (DB14513)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnesium sulphate (20 mg/kg iv bolus before anesthesia induction followed by 20 mg/kg/h until surgery completion)
Study: 34409931
Drug: Motivational interviewing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Motivational interviewing integrated with cognitive behavioural therapy (MI-CBT)
Study: 33597586
Drug: Hyaluronic acid
Normalized name: hyaluronic acid
DrugBank: Hyaluronic acid (non-animal stabilized) (DB19175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hyaluronic acid (HA; 4 ml)
Study: 34059848
Drug: Oral contraceptive
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral contraceptive pill (22%, n = 26/117)
Study: 33404379
Drug: Exposure to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exposure to anti-vaccine comments
Study: 33404379
Drug: Mainstream news
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mainstream news article discussing the flu vaccine
Study: 33995533
Drug: Chest-to-chest skin-to-skin
Normalized name: Kids-Eeze Chest Relief
DrugBank: Guaifenesin (DB00874)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chest-to-chest skin-to-skin contact (CC-SSC)
Study: 32380894
Drug: Glycopyrrolate metered
Normalized name: formoterol fumarate / glycopyrrolate Metered Dose Inhaler
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycopyrrolate metered dose inhaler (GP MDI) 18 μg
Study: 32380894
Drug: Formoterol fumarate
Normalized name: Formoterol Fumarate
DrugBank: Formoterol (DB00983)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Formoterol fumarate metered dose inhaler (FF MDI) 9.6 μg
Study: 33932031
Drug: Nelfinavir (875
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nelfinavir (875 mg orally twice daily)
Study: 33932031
Drug: Nelfinavir (1250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nelfinavir (1250 mg orally twice daily)
Study: 33932031
Drug: Nelfinavir with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nelfinavir with concurrent CRT
Study: 32279561
Drug: First-generation drug-eluting
Normalized name: Fraxinus velutina pollen
DrugBank: Fraxinus velutina pollen (DB10455)
Approvals — FDA: no, EMA: no, PMDA: no
Description: First-generation drug-eluting stents (DES1)
Study: 32279561
Drug: Second-generation drug-eluting
Normalized name: Fraxinus velutina pollen
DrugBank: Fraxinus velutina pollen (DB10455)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Second-generation drug-eluting stents (DES2)
Study: 34915485
Drug: APF-gel application
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: APF-gel application (1.23% F applied for 4 min)
Study: 36189647
Drug: Albuterol +
Normalized name: Albuterol
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albuterol + Vasoactive
Study: 32678131
Drug: Eyelid hygiene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eyelid hygiene performed twice a day for 10 days from 3 days before to 1 week after cataract surgery
Study: 32431251
Drug: PROPER intervention
Normalized name: Propel
Approvals — FDA: no, EMA: no, PMDA: no
Description: PROPER intervention (structured and repeated multidisciplinary medication review, supported by education and continuous evaluation)
Study: 36307616
Drug: Sclerotherapy (injections
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sclerotherapy (injections of ethanolamine oleate)
Study: 32852613
Drug: Emixustat hydrochloride
Normalized name: Chlorpromazine Hydrochloride
DrugBank: Emixustat (DB12608)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Emixustat hydrochloride (daily oral doses ranging from 5 to 40 mg for 84 days)
Study: 35399053
Drug: 200 IU/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 IU/d vitamin D3 (control dose)
Study: 33200813
Drug: Trimetazidine (35
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimetazidine (35 mg b.i.d.) on top of standard medical therapy
Study: 34078209
Drug: Contextual interference
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contextual interference group who putted at varied putting distances and had varied repetitive weekly schedule patterns
Study: 36448744
Drug: Topical Jessner
Normalized name: lactate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical Jessner solution
Study: 33029953
Drug: 4 ×
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 × 30‐mg tablets
Study: 33029953
Drug: 4 ×
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 × 30‐mg tablets as slurry
Study: 33063273
Drug: Plenadren (once-daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plenadren (once-daily dual-release hydrocortisone)
Study: 36115321
Drug: Testosterone administration
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone administration (single dose)
Study: 32106877
Drug: 500 mL
Normalized name: TPN Bag 500 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mL pleural lavage fluid
Study: 32106877
Drug: 3000 mL
Normalized name: TPN Bag 3000 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3000 mL pleural lavage fluid